SCHEMBL30103103

SCHEMBL30103103

COc1cc(-c2ccc(CBr)cn2)ccc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 3/20 0.55
▸ NPC1 O15118 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ CYP11B1 P15538 3/20 0.41
▸ CYP11B2 P19099 2/20 0.41
▸ CASP3 P42574 1/20 0.40
▸ SENP8 Q96LD8 1/20 0.40
▸ SENP7 Q9BQF6 1/20 0.40
▸ SENP6 Q9GZR1 1/20 0.40
▸ GRK2 P25098 1/20 0.39
▸ GRM2 Q14416 1/20 0.39
▸ FYN P06241 2/20 0.39
▸ PHF8 Q9UPP1 1/20 0.38
▸ CYP17A1 P05093 1/20 0.38
▸ PAX8 Q06710 1/20 0.38
▸ GRM5 P41594 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24785043 1.00 KDM1A (0.55) KDM1ANPC1TP53PKMRAB9A
SCHEMBL30103108 0.89 CYP17A1 (0.50) KDM1ANPC1TP53PKMRAB9A
SCHEMBL24785848 0.89 CYP17A1 (0.50) KDM1ANPC1TP53PKMRAB9A
SCHEMBL30103063 0.86 KDM1A (0.55) KDM1ANPC1TP53PKMRAB9A
SCHEMBL30103043 0.86 KDM1A (0.55) KDM1ANPC1TP53PKMRAB9A
SCHEMBL24785040 0.86 KDM1A (0.55) KDM1ANPC1TP53PKMRAB9A
SCHEMBL24785077 0.83 KDM1A (0.42) KDM1AFYNPHF8CYP17A1PAX8
SCHEMBL30103141 0.83 KDM1A (0.42) KDM1AFYNPHF8CYP17A1PAX8
SCHEMBL3162853 0.77 CA2 (0.45) SMN1; SMN2
SCHEMBL30103064 0.75 CYP17A1 (0.50) KDM1ANPC1TP53PKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115448913-A Bicyclic compounds for the treatment of EP2, EP4 receptor mediated diseases 武汉人福创新药物研发中心有限公司 2022-12-09 — — CN disclosed
Send feedback